March 15, 2013
On March 14, ASBM Advisory Board Member, Dr. Harry Gewanter was quoted in the Inside Health Policy Article “North Dakota Projects Lost Savings With Biosimilar Bill; Cost Debate Heats Up.” The article says: “Harry Gewanter, a pediatric rheumatologist and Alliance for Safe Biologic Medicines board member, rebutted arguments from the sponsor of the Virginia bill, […]
March 12, 2013
ASBM Executive Director Michael Reilly was quoted in a BNA article on biosimilar state legislation. Reproduced with permission from Pharmaceutical Law & Industry Report,11 PLIR 286 (March 1, 2013). Copyright 2013 by The Bureau of National Affairs, Inc. (800-372-1033) <http://www.bna.com> (BNA) — Will State Laws Thwart Use of Biosimilars? Major Development: Several states are considering […]
March 1, 2013
WASHINGTON – The Alliance for Safe Biologic Medicines (ASBM) today released the following statement on the sequestration budget cuts that begin to take effect on March 1. ASBM Chairman Dr. Richard Dolinar said the following: “The Affordable Care Act, enacted in March 2010, authorized the U.S. Food and Drug Administration (FDA) to develop a pathway […]
February 27, 2013
The announcement last night that Affymax (NASDAQ: AFFY) is recalling all lots of its red blood cell stimulating medicine Omontys could have broader implications for how the Food and Drug Administration (FDA) evaluates similar drugs going forward. Omontys was recalled following some fatal, severe allergic (anaphylactic) reactions that occurred within 30 minutes of receiving the […]
February 27, 2013
State Activity With the start of a new year, comes the start of a new legislative calendar. The past weeks have been very busy as many states are considering substitution legislation. ASBM and our members have been sending in letters of support in CO, VA, IN and ND and will continue to express our concerns […]
January 9, 2013
Inside Health Policy’s “Stakeholders Gear Up For Biosimilar Substitution Battle In 2013” article includes mentions of ASBM and quotes Dr. Dolinar: “Still, groups like the Alliance for Safe Biologic Medicines, which has a broad membership of patient groups and innovator biologic companies, are pressing for a unique naming scheme, saying it is pertinent for ensuring […]
December 21, 2012
On December 13th, ASBM members were invited to take a tour of a biologics manufacturing facility in Rhode Island to learn about the intricacies and complex processes involved with making biologic medicines.
December 21, 2012
On December 6th, Chairman Richard Dolinar, M.D., and Executive Director Michael Reilly toured a biologic manufacturing facility in Longmont, CO. Several ASBM members also participated on the tour which was arranged to help attendees better understand the complexities of manufacturing biologics.
December 19, 2012
The Alliance for Patient Access National Physicians Biologics Working Group released a white paper entitled, “Biologics: Can Patients Get What the Doctor Orders?” The paper examines barriers to therapeutic access resulting from current healthcare benefits design. This is a second in a series of papers designed as an educational resource to inform the public and […]
